BioNote

바이오노트 · 377740

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$352.2M (₩486B)

Overview

BioNote makes rapid diagnostic test kits and reagents used to detect diseases in animals, relying on its own technology for producing recombinant antigens and antibodies, the biological building blocks that make diagnostic tests work.

Its products are supplied to distributors and affiliated partners in multiple countries. Listed on KOSPI, Korea's main stock exchange, the company is also expanding its core biological materials, antigens, antibodies, and enzymes, into the supply chain for human in-vitro diagnostic (IVD) reagents, broadening beyond its veterinary roots.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$85.7M
▲ +15.1% YoY
Operating profit · FY2025
US$12.1M
▲ +36.8% YoY
Net income · FY2025
−US$63.4M
Turned to loss

Revenue

  • FY2023US$65.3M
  • FY2024US$74.5M
  • FY2025US$85.7M

Operating profit

  • FY2023−US$34.1M
  • FY2024US$8.9M
  • FY2025US$12.1M

Net income

  • FY2023−US$14.9M
  • FY2024US$40M
  • FY2025−US$63.4M

Key ratios (FY2025)

ROE
-5.8%
Debt/Eq
3.0%
Op. margin
14.1%
Net margin
-74.0%
Rev. YoY
▲ +15.1%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.